Introduction
HIV-1 infection is characterized by early viremia followed by a long period of clinical latency [1] [2] [3] , in which the level of virus production reflects a continuous process of new infection at a rate that balances the rapid death of productively infected cells (reviewed in 4 ). After years, when a clinically apparent disease develops, this steady-state is unbalanced towards an exponential increase in viral burden 2 . During all these steps, infected cells release soluble factors that likely contribute to the infectivity of nearby, uninfected cells 5 .
The endogenous HIV-1 transactivator of transcription Tat, although known as a nuclear factor 6 , is released by infected cells both in vitro and in vivo [7] [8] [9] , and seems to play several functions in the extracellular microenvironment. For example, a large number of results suggest that Tat could contribute to the onset of disorders associated with HIV-1 infection, i.e. Kaposi's sarcoma 7, 10 , dementia 11 , lymphomas 12 , and kidney injury 13 .
Interestingly, a direct, non-transcriptional function of Tat in the setting of a spreading viral infection has also been suggested [14] [15] [16] . Accordingly with this potential role of extracellular Tat, circulating anti-Tat antibodies (Abs) correlate with low or undetectable viral load in HIV-1 seropositive patients [17] [18] [19] . These observations are also confirmed by the ability of neutralizing anti-Tat antibodies to reduce the viral load both in vitro and in vivo [20] [21] [22] (reviewed in 23, 24 ). Despite the huge, and often controversial scientific production regarding the role of extracellular Tat, an insight into the molecular mechanism(s) responsible for a Tat-driven spreading of infection remained so far elusive.
Here we demonstrate that membrane-bound Tat is a thus far unrecognized mediator of HIV-1 entry. In particular, we show that Tat is present on the surface of HIV-1-infected and nearby uninfected cells, where it is specifically bound by HIV-1 gp120 envelope protein, leading to enhanced virus attachment and entry into cells. We also describe phage display-selected peptides that interfere with this binding, thus inhibiting HIV-1 entry and propagation of the infection. , and HIV-1 RNA ranging from 88 to 150.000 copies/ml (Table 1) .
Two frozen lymph nodes were provided by the National Cancer Institute's AIDS and Cancer Specimen Gold system (Perkin Elmer, Shelton, CT), with an annealing temperature of 58 °C. For evaluation of virus propagation, HIV-1 retrotranscriptase (RT) activity in the cell supernatants was quantified with a standard assay as described 31 . Co-cultures and incubations with Tat proteins, anti-Tat mAb, and gp120-like peptides. C8166 cells (10 6 /ml) were co-cultured with HIV-1-infected or control U937 cell, and with U937/PINCO or U937/Tat cells in 6-well transwells for 4 h (unless differently specified) at 37 °C, or incubated in culture medium containing 7 nM (unless differently specified) of the described Tat proteins for 15 min at 37 °C. When Escherichia coli bacteria at log-phase. Purification of phage particles and DNA sequencing of phagedisplayed inserts were performed as described [33] [34] [35] . Phage binding to rTat-coated microwells was performed with a 10 9 TU input of each phage clone.
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Binding assays. One microgram of rgp120 was coated per well of a 96-well plate overnight in PBS.
After blocking with 1% bovine serum albumine (BSA) in PBS, the wells were incubated in 0.1% BSA in PBS with the described GST-Tat fusion proteins, and the synthetic peptides when indicated, at a concentration of 7 nM for 1 h at room temperature. Bound Tat was stained with an anti-GST mAb (Santa Cruz Biotechnology, Santa Cruz, CA), detected by a secondary anti-mouse HRP-conjugated mAb, and quantified using the 1-Step TM Turbo TMB-ELISA kit (Pierce PBMCs from twenty HIV-1 + patients naïve for antiretroviral therapy (ART) ( Table 1) . By cytofluorimetric analysis we confirmed that up to 6% of cells from fifteen patients had detectable amounts of Tat on their
surfaces.
These results demonstrate that Tat is released by HIV-1-infected cells and is detectable on the cell surfaces both in vitro and in vivo. Tat .
HIV-1 Tat localizes at the surface of both
As assessed for HIV-1-infected PBMCs ( Figure 1A and Table   1 ), an anti-Tat immunoreactivity was localized at the cell surface of U937/Tat cells as well ( Figure 1B ).
We then determined if released Tat could bind to surfaces of nearby untransduced cells, by co-culturing U937/Tat cells with C8166 T-lymphocytes in a transwell system, in which only the exchange of soluble factors is allowed. We found that after co-culture Tat was indeed detectable on the membranes of C8166 cells ( Figure 1B ). Figure 1D ), suggesting that Tat binds to the surface of C8166 cells through its basic region.
HIV-1-infected cell-released Tat enhances virus entry into surrounding cells. To get insights into
the mechanism of a possible Tat-mediated HIV-1 infection, we set up experiments using HIV-1-derived LVs 28, 36 . In the LV system, HIV-1 genome has been modified so that (i) green fluorescent protein (GFP)
is expressed for the detection of transduced cells, and (ii) complete HIV-1 particles are assembled, but (iii) they are unable to propagate the infection. Therefore, by using LVs it is possible to evaluate early steps of the infection process. We infected U937 cells with a primary isolate from an ART-naïve subject.
Next, we evaluated LV entry into C8166 cells after co-culture with HIV-1-infected U937 cells in a transwell system. We observed that co-cultured C8166 cells were up to 50% more permissive to entry of LVs carrying the gp120 envelope of HIV-1 HXB2 (gp120-LVs) 29 . This effect was partially reversed by NT3 2D1 anti-Tat mAb, but not by control IgG (Figure 2A) . Moreover, the enhancement of gp120-LV entry was significantly higher when the co-culture was performed with U937 cells 6 days from primary infection, compared to co-culture with U937 cells 3 days post-infection ( Figure 2A ).
These results suggest that HIV-1-infected cell-released Tat is responsible of the increase in gp120-LV entry into target cells. These data demonstrate that the increase in cell entry is strictly dependent not only on surface-bound
Membrane-bound
Tat, but also on the presence of an HIV-1 gp120 envelope protein.
Tat is a specific, high affinity ligand of the HIV-1 gp120 envelope protein. We reasoned that Tat and gp120 could interact at the cell surface, thus enhancing gp120-LV entry into cells. To test this hypothesis, we performed SPR analysis to evaluate whether rTat directly interacted with the gp120
protein. BIAcore sensor chips were coated with rTat and exposed to rgp120. A specific binding between these proteins was detected (K d = 8.1 ± 0.3 nM, Figure 3A ).
We then mapped the region(s) of gp120 involved in Tat binding, by using phage-displayed peptide libraries. Tat-binding peptide motifs were selected after multiple rounds of biopanning on U937/Tat cells.
In this system, Tat is concentrated at the cell surface in a conformation that is functionally active in binding the viral envelope. Two different random peptide libraries were used, with the general structures CX 10 C, and CX 3 CX 3 CX 3 C (C = cysteine, X = any aminoacid). The libraries were pre-cleared on U937/PINCO cells, and the remaining phage were exposed to U937/Tat cells. Sequencing of the phage isolated after selection revealed two peptides that were preferentially enriched, CTVECYFNCTPTC and CPDRKKKVVMVC. Both peptide sequences share homology (bold letters) with a portion of the V1/V2 loop within the gp120 protein, between aa 157-171 of gp120 HXB2 (  38 and Table 2 ). Tat-binding phage only.
For
to rTat-coated microwells. Phage carrying either CTVECYFNCTPTC or CPDRKKKVVMVC peptide specifically bound rTat ( Figure 3B ), suggesting that these peptides mimic the region of gp120 that interacts with Tat. To further investigate the involvement of gp120 V1/V2 loop in mediating Tat binding, we synthesized soluble peptides designed on a consensus among sequences of the gp120 V1/V2 loops of several HIV-1 strains 38 (peptides #CT303 = CSFNIT, #CT304 = RDKVKK and #CT319 = CSFNITTEIRDKVKK, see Table 2 ). We evaluated GST-Tat 86 binding to rgp120-coated microwells in the presence of increasing peptide concentrations. All the peptides inhibited Tat/gp120 binding, #CT319
showing the highest efficiency ( Figure 3C ). In these experiments, #CT304 showed a complete doseresponse effect, while the displacement was not increased by adding concentrations higher than 10 nM and 1 mM for #CT319 and #CT303, respectively.
To identify the region(s) of Tat required for gp120 binding, GST-Tat 86 , GST-Tat 72 , GST-Tat Bas and GSTTat Cys 25 were tested for their ability to bind gp120. All variants except for GST-Tat 72 bound to rgp120-coated microwells, suggesting that the interaction with gp120 is mediated by Tat aa 73-86 ( Figure 3D ).
To reinforce this finding, we evaluated which Tat mutant retained the ability to enhance LV entry into cells. Because Tat protein released by 293T packaging cells might be present in gp120-LV preparations, we produced Tat-deficient   30 , gp120-coated LVs (Tat -/gp120-LVs), to completely eliminate any background. We treated C8166 cells with each GST-Tat variant before incubation with Tat -/gp120-LVs, and found that both GST-Tat 72 (which does not bind gp120, Figure 3D ) and GST-Tat Bas (which does not bind the cell surface, Figure 1D ) were unable to enhance Tat -/gp120 entry into C8166 cells ( Figure 3E ). Tat-treated PBMCs compared to untreated PBMCs, regardless of virus strain ( Figure 4A ). Next, we asked whether Tat-mediated increase of HIV-1 entry could be a crucial step in virus spreading. To answer this question, we followed PBMC infection along 21 days as HIV-1 RT activity in cell supernatants. rTat-treated PBMCs showed an early peak of Ba-L HIV-1 production, which at day 6 was up to ten-fold higher than in control infections ( Figure 4B ). Similar results were obtained with III B HIV-1 (data not shown).
These in vitro data suggest that Tat amplifies the spreading of HIV-1 infection in PBMCs by enhancing virus entry into host cells.
In vivo, Tat is detectable on the surfaces of both gp120
-and gp120 + cells. To confirm that the described interaction possibly represents a physiological mechanism in the spreading of HIV-1, we evaluated the presence of Tat and gp120 on biological specimens from HIV-1-infected, ART-naïve patients. Five PBMC samples (#ARRA, #BALS, #BRARO, #KOJE, and #VEBE, see Table 1 ) and two lymph node biopsies (#UMB00-003 and #GW97-91, see Methods) were simultaneously stained with NT3 2D1 anti-Tat and CRA3 anti-gp120 mAbs. In both infected compartments we observed three different populations: a) Tat + cells, b) gp120 + cells, and c) cells positive for both antigens, whit region of possible co-localization ( Figure 5 ; results of Tat staining on samples #BALS, #BRARO and #VEBE are also shown in Table 1 ). These results demonstrate that in specimens from HIV-1 + patients (i) cells with no detectable staining for gp120 may be covered by Tat, thus representing potential targets for only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From enhanced HIV-1 infection, and (ii) Tat and gp120 could be simultaneously present on the cell surface, suggesting that they could interact in vivo. gp120-mimic peptides revert Tat-driven HIV-1 entry and spreading. Finally, we evaluated whether synthetic gp120-mimic peptides could block Tat-mediated HIV-1 infection. We first investigated if the gp120-mimic peptides could block virus entry. We incubated the peptides with C8166 cells at increasing concentrations; accordingly to gp120/Tat displacement shown in Figure 3C , we chose incubations ranging from 10 to 100 µM for #CT303 and #CT304, and from 10 nM to 1 µM for #CT319. An unrelated peptide (GACVRLSACGA) was used as a negative control. For infection experiments we used supernatants of infected cells, in which Tat is already present ( Figure 1A ). In these experimental conditions, the gp120-mimic peptides specifically inhibited entry of both HIV-1 strains ( Figure 6A ). We also performed infections after incubation of cells with rTat (as shown in Figure 4A ); under these conditions, as expected the gp120-mimic peptides exhibited substantially enhanced efficacy in inhibiting infection (similar results were obtained with both viral strains, Figure 6B ).
We next investigated the effect of gp120-mimic peptides on the spreading of viral infection. rTat-treated
PBMCs were infected in presence of #CT319 peptide, which completely abolished rTat-driven virus propagation at a concentration as low as 1 nM ( Figure 6C , compare to Figure 4B ). We also evaluated the efficacy of #CT319 to inhibit endogenous Tat-mediated HIV-1 infection. For this purpose, we added the peptide to infected PBMCs every 72 h either at 1 or 10 nM concentration. Both III B and Ba-L production was inhibited by #CT319 ( Figure 6D) , with a marked inhibitory effect detectable after 6 to 10 days post primary infection, by which time Tat is released into the culture medium and binds the cell surface ( Figure 1A) . To confirm the specificity of this inhibition, we performed infections in which #CT319 was added as a single administration at different time points after primary infection. With an administration at day 7 the infection was delayed, at day 10 it was inhibited, and at day 14 (peak of surface-bound Tat, Figure 1A ) it was completely blocked ( Figure 6E ).
These results demonstrate that Tat-driven infection is specifically reverted by a gp120-mimic peptide that possibly interferes with Tat/gp120 interaction at the cell surface. 
Discussion
Our results provide evidence for a novel mechanism of HIV-1 entry, which could be a new therapeutic target to control infection and spreading of the virus.
We started from the observation that HIV-1-infected cells promote virus entry into nearby cells ( Figure   2A ). This effect is mediated by infected cell-released Tat and is consistent with Tat production observed in vitro in the onset of an acute infection ( Figure 1A) . We show that extracellular Tat is concentrated on the surfaces of both HIV-1 infected and surrounding, uninfected cells both in vitro and in vivo ( Figure 1 and Table 1 ). We hypothesized that the cell surface could function as a reservoir for Tat, which, in that context, could enhance virus entry. This hypothesis first rose from the observation that the basic domain of Tat is responsible for its uptake by cells 39, 40 ; this property has been used to promote intracellular delivery of nucleic acids 41, 42 Our results provide evidence that Tat-driven enhancement of HIV-1 entry is a consequence of specific interactions between Tat and gp120 at the cell surface ( Figure 3) . Interestingly, rTat enhances LV entry of 50% at a 7 nM concentration, close to the Kd value for Tat/gp120 binding, as evaluated by SPR analysis (Kd ∼ 8 nM, Figure 3A) . The peak of Tat-induced enhancement of LV-transduced cells is reached at 70 nM ( Figure 2C ), which is 10 to 100 fold higher than Tat amounts detected in infected sera 9 . However, heparan sulfate proteoglycans sequester and concentrate Tat at the cell surface 8, 37 , making it possible to obtain high local concentration of Tat both in vitro and in vivo ( Figure 1 , Table 1 ). Moreover, in lymphoid tissue, viral load and Tat amounts go beyond by orders of magnitude than in bloodstream 47, 48 .
Our results also indicate that Tat-mediated enhancement of LV-transduced cells is independent from its transactivating activity. First, we observed that Tat concentrations and incubation times not sufficient to only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From involve genes transcriptionally modulated by Tat 49 were optimal to increase virus entry ( Figure 2C ). On the contrary, cells that were exposed to higher doses of Tat ( Figure 2C ), or incubated for longer periods of time ( Figure 2D ), were not efficiently transduced by gp120-LVs. Tat-mediated induction of apoptosis could explain this observation 9, 50 . Alternatively, one could reason that an interaction with the HIV-1 coreceptor CXCR4 could lead to inhibition of LV entry [51] [52] [53] . Furthermore, the fact that Tat is not able to enhance the numbers of VSV-G-LV-transduced cells excludes any unspecific, post-entry effect on LV integration and/or on GFP production ( Figure 2D-E) .
We demonstrate that the regions involved in Tat/gp120 interaction are the V1/V2 loop of the envelope protein (by mean of phage-displayed peptide libraries) and the second exon of Tat (by mean of GSTfused Tat mutants) (Figure 3 ). The V1/V2 loop is exposed in the context of the protein structure, suggesting that this is a site that could interact with viral receptors. However, this region is not directly involved in binding the HIV-1 receptor CD4, or co-receptors such as CCR5 and CXCR4 [54] [55] [56] . Moreover, despite the high variability of the V1/V2 loop, the portion mapped by the phage display-selected peptides is conserved, particularly the "C-S/T/E-F-basic-apolar-S/T" and the "R/K-D/N-basic stretch" motifs (  38 and   Table 2 ), suggesting a functional role for this region. For what concerns Tat, we found that both the second exon and the basic domain are necessary for enhancing LV entry; although retaining the ability to bind gp120, GST-Tat Bas was ineffective being unable to bind the cell surface ( Figure 1D ). In the experiments with Tat recombinant proteins, we used the 86-aa Tat from the laboratory-adapted HIV-1 strains III B (rTat) and HXB2 (GST-fused Tat variants); sequence alignments show that this region is strongly conserved also in 101-aa Tat proteins from HIV-1 wild type strains ( Table 3 ), suggesting that aa 87-101 may be dispensable for the described mechanism. Intriguingly, 7 out of 15 aa are identical or homologous also in Tat proteins from different HIV-2 strains (Table 3) ; on the basis of these homologies, one could speculate Tat-mediated enhancement of virus entry be possible also for HIV-2 infection.
A previously published work 57 shows data both in agreement and in apparent contrast with our results, which need discussion. Tat-mediated effects are various and complex, but for the present discussion one could assume that it has two roles in virus propagation: entry (enhanced infection) and transactivation (production of new viral particles). In the cited paper, a role for Tat second exon in viral only.
One may speculate that this effect is due to the absence of Tat-mediated virus entry, being effective only basal entry plus transactivation. With a specular experiment, we show an earlier peak of virus replication by treating cells with rTat immediately before the infection (Fig. 4) . In this case, the effect is due to basal virus entry plus transactivation plus Tat-mediated virus entry.
The proportion of Tat-mediated virus entry seems to be strictly dependent on the cell type. This is an interesting issue, which could be related to the number or the availability of receptors on the cell surfaces, as well as to other so far unknown players in the complex system of virus/cell recognition and infection. It is much interesting to observe that, as described in 57 , infection of PBMCs is almost completely blocked in absence of Tat second exon. Such a result, obtained with transactivation competent Tat first exon variants, might suggest Tat-mediate virus entry be of pivotal importance in primary cells, i.e. in these cells transactivation is not sufficient to sustain virus growth due to an inefficient basal entry. This raises an intriguing speculation: primary cells lack a molecular adjuvant of virus entry in the absence of Tat, or they have a molecular block that does not allow entry in basal conditions. This means that Tat may use different molecules instead of or together with HIV-1 classical receptors. We are currently investigating this point.
In the cited paper 57 , the authors describe several mutants of both first exon and full length Tat, whose behaviour could somehow contrast with our results. Four mutants of full length Tat have mutations in the first exon that do not influence or just slightly modify transactivation; however, those mutants show either a complete absence or a delay of replication. These results involve Tat first exon in transactivationindependent viral replication. One can speculate that (i) some mutations in the first exon change Tat 3D structure, influencing the availability of the second exon for gp120 binding; (ii) Tat regions other than the second exon are involved in gp120 binding; (iii) Tat first exon is needed for interactions with other known (receptors, co-receptors, surface proteoglycans) or unknown molecular players. Interestingly, a mutation in the region 73-86 of the second exon leads to delayed virus proliferation without influencing transactivation, confirming our model. On the other hand, a mutation in a downstream region causes an increase in virus replication without influencing transactivation: this means that aa in the region 87-101
by changing the 3D structure of the 73-86 region and/or its affinity for gp120. However, mutations in the second exon appear to be very rare, confirming a pivotal role for this region in virus proliferation.
In spite of the huge amount of data on the extracellular effects of Tat and its role in the pathogenesis of HIV-1-associated diseases, the present report demonstrates for the first time a specific role in HIV-1 infectivity. It is well known that HIV-1 infection is mainly dependent on the presence of CD4 and CXCR4/CCR5; we propose that surface-bound Tat could partially enhance HIV-1 entry into host cells (Figure 2 and 4) . We also provide evidence that the Tat/gp120 interaction is likely to occur in vivo during viral spreading, as demonstrated by the co-localization of anti-Tat and anti-gp120 staining both on PBMCs and in lymph node biopsies from HIV-1 + patients ( Figure 5 ). Our experiments show that Tat can enhance the entry of viruses that use either CXCR4 (III B) or CCR5 (Ba-L) as co-receptors ( Figure 4A ), suggesting a broad-range mechanism for Tat-driven HIV-1 infection. Since virus spreading follows an exponential trend, an increase in HIV-1 entry as low as 60% is sufficient to give a ten-fold increase in virus production after 6 days from primary infection ( Figure 4B ).
We also investigated the potential use of the phage display-selected peptides as drugs against HIV-1 infection. We observed that these peptides compete with gp120 V1/V2 loop for Tat binding in vitro ( Fig.   3C ) and suggested that they can inhibit this interaction on the cell surface; accordingly with this hypothesis, we observed that the gp120-mimic peptides do not interfere with Tat transactivation activity (S. Marchiò, unpublished data). We observed that both virus entry and propagation are significantly blocked by the gp120-mimic peptides in a Tat-dependent manner; this effect is independent from the viral strain ( Figure 6 ). These results are consistent with the observation that the region of V1/V2 loop involved in Tat binding is quite conserved along different HIV-1 strains 38 . Based on our experimental data, we propose that gp120-like peptidomimetic derivatives could be developed as broad-range anti-AIDS drugs, to be used in association with other antiretroviral therapies.
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